DVT Management
For most patients with DVT, initiate treatment with direct oral anticoagulants (DOACs) over vitamin K antagonists, and manage as an outpatient unless specific high-risk features are present. 1
Initial Treatment Setting
Outpatient management is preferred for uncomplicated DVT 1. Home treatment should be offered over hospitalization for patients who:
- Lack other conditions requiring admission
- Have adequate home support
- Can afford medications and have good adherence history
- Are not at high risk for bleeding
- Do not require IV analgesics
Clinical prediction scores like PESI can help identify low-risk patients, though they have only moderate predictive ability and don't replace clinical judgment 1.
Anticoagulation Choice
First-Line Therapy
DOACs are preferred over warfarin (VKAs) based on moderate certainty evidence 1. This recommendation prioritizes reduced mortality and major bleeding risk while maintaining efficacy.
Important exceptions where DOACs may not apply:
- Creatinine clearance <30 mL/min
- Moderate to severe liver disease
- Antiphospholipid syndrome 1
DOAC Selection
No single DOAC is superior to another 1. Selection should be based on:
- Need for lead-in parenteral anticoagulation (rivaroxaban and apixaban don't require this)
- Dosing frequency preference (once vs twice daily)
- Out-of-pocket cost
- Renal function
- Drug interactions (CYP3A4/P-glycoprotein metabolism)
- Presence of cancer
Monitoring Requirements
Renal function monitoring is essential 2:
- CrCl ≥50 mL/min: Monitor every 6-12 months
- CrCl <50 mL/min: Monitor approximately every 3 months
Thrombolysis Considerations
For Proximal DVT
Anticoagulation alone is preferred over adding thrombolysis in most patients 1. This avoids the increased major bleeding risk without clear mortality benefit.
Thrombolysis is reasonable only for:
- Limb-threatening DVT (phlegmasia cerulea dolens) - this is the clearest indication
- Selected younger patients at low bleeding risk with symptomatic iliofemoral DVT who strongly value rapid symptom resolution and accept bleeding risk to potentially reduce post-thrombotic syndrome 1
Avoid thrombolysis for DVT limited to veins below the common femoral vein 1.
Catheter-Directed vs Systemic Thrombolysis
If thrombolysis is indicated for extensive DVT, use catheter-directed over systemic thrombolysis 1, though evidence certainty is very low.
Common Pitfalls to Avoid
Don't hospitalize uncomplicated DVT patients reflexively - this increases costs without improving outcomes 1
Don't use DOACs in severe renal insufficiency (CrCl <30 mL/min) - warfarin is safer in this population 1
Don't overuse thrombolysis - the bleeding risk outweighs benefits except in limb-threatening situations or carefully selected young patients with iliofemoral involvement 1
Don't forget to assess bleeding risk before any thrombolytic therapy - this is critical for patient selection 1
Special Populations
For patients with cancer-associated DVT, DOAC choice may be influenced by cancer type and concomitant medications 1. For patients with antiphospholipid syndrome, warfarin remains preferred over DOACs 1.
Management After Major Bleeding
If major bleeding occurs during anticoagulation, resume therapy within 90 days rather than discontinuing permanently, provided the patient requires long-term anticoagulation, is not at high risk for recurrent bleeding, and is willing to continue 2. This balances the competing risks of recurrent thrombosis versus bleeding.